Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedPAC urges fix for charge compression

This article was originally published in The Gray Sheet

Executive Summary

CMS should immediately correct for charge compression, a payment calculation phenomenon that generally leads to the undervaluing of high-cost technology, says the Medicare Payment Advisory Commission in Sept. 14 1comments to the agency. Despite similar pressure from device stakeholders to use regression analysis for a near-term fix to the problem, CMS said in its July proposal for 2008 hospital outpatient payments that it wants to further study the approach (2"The Gray Sheet" July 23, 2007, p. 17). "The issue of charge compression is serious enough that CMS should move forward with this imperfect solution," MedPAC writes. CMS will finalize the decision by Nov. 1

You may also be interested in...



CMS Declines To Act On Charge Compression In 2008 Outpatient Proposal

CMS wants to examine hospital outpatient charge data more carefully before making any Medicare payment adjustments to remedy charge compression, the agency explains in its 2008 outpatient payment proposed 1rule

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel